T. Rowe Price Investment Management Inc. Acquires New Position in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

T. Rowe Price Investment Management Inc. bought a new position in shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm bought 82,165 shares of the company's stock, valued at approximately $1,757,000. T. Rowe Price Investment Management Inc. owned approximately 0.55% of Jasper Therapeutics as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of JSPR. Schroder Investment Management Group acquired a new stake in Jasper Therapeutics during the 4th quarter valued at $1,237,000. Russell Investments Group Ltd. increased its stake in shares of Jasper Therapeutics by 16.9% in the fourth quarter. Russell Investments Group Ltd. now owns 247,272 shares of the company's stock valued at $5,287,000 after buying an additional 35,746 shares in the last quarter. State Street Corp increased its stake in shares of Jasper Therapeutics by 12.3% in the third quarter. State Street Corp now owns 214,883 shares of the company's stock valued at $4,042,000 after buying an additional 23,564 shares in the last quarter. Simplify Asset Management Inc. bought a new position in shares of Jasper Therapeutics in the fourth quarter valued at about $428,000. Finally, Jane Street Group LLC bought a new stake in Jasper Therapeutics during the 3rd quarter worth about $251,000. Institutional investors own 79.85% of the company's stock.

Jasper Therapeutics Stock Performance

JSPR traded up $0.03 during midday trading on Friday, reaching $5.41. 125,884 shares of the company were exchanged, compared to its average volume of 288,401. The stock has a market capitalization of $81.27 million, a P/E ratio of -1.14 and a beta of 2.55. Jasper Therapeutics, Inc. has a one year low of $3.13 and a one year high of $26.84. The stock's 50-day simple moving average is $4.77 and its 200 day simple moving average is $12.02.

Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($1.62) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.35). On average, research analysts anticipate that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on JSPR. UBS Group initiated coverage on shares of Jasper Therapeutics in a research note on Thursday, February 13th. They set a "buy" rating and a $38.00 price target on the stock. HC Wainwright reissued a "buy" rating and issued a $40.00 target price on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. Royal Bank of Canada dropped their target price on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a research report on Thursday, January 9th. Finally, JMP Securities reiterated a "market outperform" rating and issued a $70.00 price target on shares of Jasper Therapeutics in a report on Monday, January 6th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Jasper Therapeutics currently has an average rating of "Buy" and an average price target of $62.50.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.